Clin2
NCT06939088Possibly a fitRecruiting

Tirzepatide for alcohol reduction in schizophrenia

Alcohol Use DisorderAlcohol Abuse/DependenceAlcohol DependenceAlcoholismSchizophrenia DisordersSchizophrenia and Disorders With Psychotic FeaturesSchizophrenia and Schizophrenia Spectrum PsychosisSchizophrenia

Treatments studied

Part of Mental health clinical trials.

This trial tests if tirzepatide, a once-weekly injection, can help reduce heavy drinking in people who have both schizophrenia and alcohol use disorder. If you struggle with alcohol and have stable schizophrenia, this study may offer a new treatment option.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
108 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old.
  • You have a diagnosis of both schizophrenia and alcohol use disorder.
  • You have had at least 4 heavy drinking days in any 3-week period over the past month (heavy = 4+ drinks for women, 5+ for men).
  • You have a body mass index (BMI) of 23 or higher.
  • You do not currently have severe psychosis or suicidal thoughts.
  • You are not using other alcohol treatment medications like naltrexone or disulfiram.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06994338Recruiting· Phase 2
Tirzepatide for alcohol use disorder

This study tests whether a medication called tirzepatide (a once-weekly injection) can help people reduce their alcohol consumption. It is for people who drink heavily, have a high BMI, and are actively seeking help to drink less.

Los Angeles, California
NCT07046819Recruiting· Phase 2
Tirzepatide for liver disease linked to alcohol use

This trial tests if tirzepatide, a medication that helps with weight and blood sugar, can improve liver health in people with alcohol use disorder who also have fatty liver disease. It aims to reduce liver fat and related risks.

Bethesda, Maryland
NCT07292519Not yet recruiting· Phase 2
Tirzepatide and counseling for alcohol use and weight

This study tests whether a weekly injection of tirzepatide (a medicine for weight and blood sugar) combined with cognitive-behavioral therapy (counseling) can help people with alcohol use disorder who are also overweight or obese. By reducing alcohol cravings and supporting weight loss, the treatment aims to improve both drinking and health outcomes.

Sydney, New South Wales
NCT06727331Recruiting· Phase 2
Tirzepatide for alcohol use recovery

This trial tests if tirzepatide, a medication that helps with appetite and blood sugar, can help people with alcohol use disorder drink less or stop drinking. You would visit the clinic regularly and receive the drug or a placebo.

Boston, Massachusetts
NCT07559500Recruiting· Phase 1
Study of tirzepatide for alcohol use disorder

This trial tests if tirzepatide, a diabetes drug, affects brain chemistry linked to alcohol use. Researchers want to see if it can help people with mild-to-moderate alcohol use disorder who also have tried stimulants.

Bethesda, Maryland
NCT07758231Not yet recruiting· Phase 1
How tirzepatide affects alcohol processing

This study looks at how the diabetes medication tirzepatide affects the way your body processes alcohol. It may help us understand if this drug changes how alcohol affects you.

Madison, Wisconsin

Hear when a new Alcohol Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.